NDC properties for "testosterone 1.62 % Transdermal Gel, 2.5 GM" (RxCUI 1597126)
About this data
The tables show NDC propoerties for testosterone 1.62 % Transdermal Gel, 2.5 GM with the RxCUI 1597126
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for testosterone 1.62 % Transdermal Gel, 2.5 GM (RxCUI 1597126)
| ANDA | ANDA204268 |
|---|---|
| ANDA | ANDA204570 |
| ANDA | ANDA205781 |
| MMSL_CODE | BD29528 |
| MMSL_CODE | CD29528 |
| RxCUI | 1597126 |
| SPL_SET_ID | 2d55b825-8eab-4091-bdf2-9c52d111b8eb |
| SPL_SET_ID | 4f3c2c0a-7dab-4b50-9cae-869c3c2a8498 |
| SPL_SET_ID | 54fcdcb9-fb0e-4164-9e51-f2a5feae3217 |
| VUID | 4038388 |
| Prescribable Synonym | testosterone 1.62 % (40.5MG / 2.5GM) Transdermal Gel |
| RXNAV_STR | 2500 MG testosterone 0.0162 MG/MG Topical Gel |
| RxNorm Name | 2500 MG testosterone 0.0162 MG/MG Topical Gel |
| RxNorm Synonym | testosterone 1.62 % Transdermal Gel, 2.5 GM |
| Related queries | Interactions (for RxCUI 1597126) |
NDC Properties
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292625
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-25 |
| NDC Item | 00591292625 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 00591292630
| NDC 9 | 0591-2926 |
|---|---|
| NDC 10 | 0591-2926-30 |
| NDC Item | 00591292630 |
| Packaging | 30 PACKET in 1 CARTON (0591-2926-30) / 2.5 g in 1 PACKET (0591-2926-25) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2926 |
NDC Item 16714096901
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-01 |
| NDC Item | 16714096901 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 16714096902
| NDC 9 | 16714-969 |
|---|---|
| NDC 10 | 16714-969-02 |
| NDC Item | 16714096902 |
| Packaging | 30 PACKET in 1 CARTON (16714-969-02) / 2.5 g in 1 PACKET (16714-969-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-969 |
NDC Item 45802036602
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-02 |
| NDC Item | 45802036602 |
| Packaging | 2.5 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 45802036665
| NDC 9 | 45802-366 |
|---|---|
| NDC 10 | 45802-366-65 |
| NDC Item | 45802036665 |
| Packaging | 30 PACKET in 1 CARTON (45802-366-65) / 2.5 g in 1 PACKET (45802-366-02) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-366 |
NDC Item 68382036213
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-13 |
| NDC Item | 68382036213 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |